International Journal of Hematology and Oncology 2022, Vol 32, Num 3 Page(s): 103-109
Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma

Huseyin Salih SEMIZ1, Seher Nazlı KAZAZ2, Necla DEMIR3, Zeynep Gulsum GUC4, Tugba YAVUZSEN5, Hulya ELLIDOKUZ5, Ilhan OZTOP5, Isil SOMALI5

1Tepecik Training and Research Hospital, Department of Medical Oncology, Izmir, TURKEY
2Karadeniz Technical University, Farabi Hospital, Department of Medical Oncology, Trabzon, TURKEY
3Sivas Medicana Hospital, Department of Medical Oncology Sivas, TURKEY
4Katip Çelebi University Atatürk Education and Research Hospital, Department Of Medical Oncology, İzmir, TURKEY
5Dokuz Eylul University, Institute of Oncology, Department of Clinical Oncology, Izmir, TURKEY

Keywords: Melanoma, Adjuvant, Inflammation, Neuthrophil, Lymphocyte
The prognosis of melanoma is extremely poor. There are no biomarker that indicate the prognosis. The indirect markers of the antitumoral response such as the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), derived NLR (dNLR), absolute neutrophil count (ANC), absolute lymphocyte count (ALC) etc. have recently begun to be emphasized. Increased NLR, PLR and dNLR as a consequence of chronic inflammation have been found to be associated with poor prognosis in many cancers. The aim of this study is explore the role of this parameters in patients with early-stage melanoma. We retrospectively evaluated 120 patients admitted to our clinic with stage I-III melanoma with ANC, ALC, absolute platelet count(APC), as well as NLR, dNLR, and PLR values at the time of diagnosis, relaps and metastasis and evaluate their impact on prognosis. Patients with active infection, receiving steroids, with a chronic inflammatory disease that may alter the hematological parameters, and those with another malignancy other than melanoma were excluded. The median follow-up was 52 months. OS and DFS were significantly worse in patients with an NLR above 2.84. Also, in patients with a dNLR value above 1.96 (p= 0.007). The were no relationship between PLR value, OS and DFS, and between gender and OS. OS was significantly lower in patients over 65 years of age (p< 0.001). These results suggested that haematological parameters can be used to estimate the prognosis of melanoma. These results suggested that haematological parameters can be used to estimate the prognosis of melanoma.